NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,742 | -91.1% | 11,700 | -53.4% | 0.00% | – |
| Q3 2022 | $76,000 | -48.6% | 25,100 | -32.9% | 0.00% | – |
| Q2 2022 | $148,000 | -81.5% | 37,400 | -73.9% | 0.00% | -100.0% |
| Q1 2022 | $799,000 | -31.0% | 143,421 | +73.4% | 0.00% | -50.0% |
| Q4 2021 | $1,158,000 | -40.4% | 82,697 | -23.7% | 0.00% | 0.0% |
| Q3 2021 | $1,943,000 | -32.1% | 108,369 | -34.1% | 0.00% | -60.0% |
| Q2 2021 | $2,861,000 | -9.5% | 164,321 | +1.4% | 0.01% | -16.7% |
| Q1 2021 | $3,162,000 | +38.9% | 162,021 | +27.7% | 0.01% | +100.0% |
| Q4 2020 | $2,276,000 | +12.6% | 126,866 | +5.9% | 0.00% | -40.0% |
| Q3 2020 | $2,022,000 | -31.7% | 119,759 | -9.3% | 0.01% | -37.5% |
| Q2 2020 | $2,959,000 | +36.0% | 131,993 | +9.5% | 0.01% | +14.3% |
| Q1 2020 | $2,176,000 | -40.4% | 120,494 | -31.5% | 0.01% | -22.2% |
| Q4 2019 | $3,653,000 | +44.3% | 175,890 | +24.4% | 0.01% | +28.6% |
| Q3 2019 | $2,532,000 | +35.9% | 141,431 | +170.1% | 0.01% | +16.7% |
| Q2 2019 | $1,863,000 | +66.5% | 52,369 | +57.3% | 0.01% | +100.0% |
| Q1 2019 | $1,119,000 | -54.0% | 33,300 | -54.0% | 0.00% | -62.5% |
| Q4 2018 | $2,433,000 | -58.0% | 72,362 | -23.9% | 0.01% | -33.3% |
| Q3 2018 | $5,798,000 | -15.4% | 95,100 | +47.4% | 0.01% | -25.0% |
| Q2 2018 | $6,853,000 | 0.0% | 64,500 | 0.0% | 0.02% | 0.0% |
| Q1 2018 | $6,853,000 | -3.7% | 64,500 | -45.9% | 0.02% | -38.5% |
| Q4 2017 | $7,115,000 | +175.2% | 119,131 | +10.6% | 0.03% | +160.0% |
| Q3 2017 | $2,585,000 | +24.8% | 107,700 | +0.6% | 0.01% | +11.1% |
| Q2 2017 | $2,071,000 | +41.6% | 107,105 | -10.2% | 0.01% | +28.6% |
| Q4 2016 | $1,463,000 | -8.7% | 119,206 | +26.0% | 0.01% | 0.0% |
| Q3 2016 | $1,603,000 | +150.1% | 94,580 | +106.1% | 0.01% | +75.0% |
| Q2 2016 | $641,000 | – | 45,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |